Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors
Neoplasms
DRUG: BAY79-4620
Adverse Event reporting, Approximately 3 years after initiation of the trial|Pharmacokinetics profile of BAY79-4620, End of cycle 2 (14 days per cycle)
Biomarkers evaluation, Approximately 3 years after initiation of the trial|Tumor response evaluation, Approximately 3 years after initiation of the trial|Immunogenicity evaluation, Approximately 3 years after initiation of the trial
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors